Gregory Burshtein
CIK: 0002026002
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ENTX
Entera Bio Ltd.
Officer
Discretionary Trading P&L
Holdings
About Burshtein Gregory
Burshtein Gregory (SEC CIK 0002026002) files insider reports with the SEC as Chief of R&D of Entera Bio Ltd. (ENTX).
Signal8 holds 3 ownership filings by Burshtein Gregory, all Form 4s, filed between Jul 18, 2025 and Aug 7, 2026. Those filings report 3 transactions, from Jul 16, 2025 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Burshtein Gregory's filings is in JERUSALEM.
Recent filings by Burshtein Gregory
Other insiders filing for Entera Bio Ltd. (ENTX)
- Camisasca Riccardo Paolo, Chief Medical Officer
- Malca Yonatan, Director
- Taitel Haya, Director
- Ellis Sean, Director
- Yaacov-Garbeli Dana, Chief Financial Officer
- Galitzer Hillel, Chief Operating Officer